Clinical studies indicate that the combination of nivolumab and chemotherapy in first-line therapy improves overall survival (OS) in PD-L1-positive GC patients, with approvals in Europe, the USA, and Taiwan (5). This evidence concerns the gene CD274 and gastric cancer.